ENSC Ensysce Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1716947 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY37.9%
TTM net income YoY-729.4%
TTM EPS YoY-18.3%
Revenue 3-yr CAGR25.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,477.0%
Net margin-1,470.4%
FCF margin—
EBITDA margin-1,476.6%
Returns
ROE-635.4%
ROA-533.3%
ROIC (approx.)—
Asset turnover0.36x
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.02x
Interest coverage-7,157.58x
Cash quality & payout
Operating cash flow / net income0.09x
Accruals ratio-484.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.18M | $1.16M | $960,999 | $1.88M | $493,104 | $1.37M | $1.32M | $1.30M |
| R&D expense | $3.18M | $2.47M | $3.35M | $3.61M | $2.95M | $1.92M | $1.89M | $3.80M |
| SG&A expense | $1.59M | $1.27M | $1.18M | $1.05M | $1.28M | $1.20M | $1.40M | $1.08M |
| Operating income | -$82.50M | -$2.58M | -$3.56M | -$2.78M | -$3.74M | -$1.75M | -$1.97M | -$3.58M |
| Interest expense | $3,147 | $320 | $3,923 | $5,382 | $6,369 | $3,160 | $3,856 | $10,753 |
| Net income | -$82.11M | -$2.57M | -$3.56M | -$2.77M | -$3.73M | -$1.73M | -$1.95M | -$3.56M |
| EBITDA | -$82.49M | -$2.57M | -$3.56M | -$2.78M | -$3.74M | -$1.75M | -$1.97M | -$3.58M |
| EPS (basic) | -4.52 | -0.20 | -0.52 | — | -1.29 | -0.79 | -1.39 | — |
| EPS (diluted) | -4.52 | -0.20 | -0.52 | — | -1.29 | -0.79 | -1.39 | — |
| Weighted avg. shares (diluted) | 18.19M | 13.04M | 6.84M | — | 2.89M | 2.20M | 1.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $29.67M | $676,704 | $745,482 | $4.31M | $1.67M | $2.21M | $3.05M | $3.50M |
| Current assets | $30.80M | $2.85M | $2.01M | $7.25M | $2.93M | $5.28M | $4.40M | $5.34M |
| PP&E, net | $156,279 | $111,063 | $117,596 | $124,129 | $123,643 | — | — | — |
| Total assets | $30.95M | $2.96M | $2.17M | $7.45M | $3.18M | $5.57M | $4.61M | $5.60M |
| Current liabilities | $3.84M | $4.07M | $2.84M | $4.57M | $2.30M | $2.51M | $1.76M | $2.21M |
| Total liabilities | $3.84M | $4.07M | $2.84M | $4.57M | $2.30M | $2.51M | $1.89M | $2.22M |
| Shareholders' equity | $27.44M | -$781,697 | -$340,042 | $3.21M | $1.20M | $3.39M | $3.05M | $3.71M |
| Shares outstanding | 19.46M | 16.23M | 9.28M | 4.57M | 3.18M | 2.39M | 1.64M | 1.36M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.40M | -$1.96M | -$3.50M | -$1.53M | -$1.87M | -$2.71M | -$1.71M | -$764,090 |
| Capital expenditure | — | — | — | $0 | — | — | — | — |
| Free cash flow | — | — | — | -$1.53M | — | — | — | — |
| Investing cash flow | — | — | — | $0 | — | — | — | — |
| Financing cash flow | $19.24M | $1.89M | -$63,947 | $4.16M | $1.45M | $1.87M | $1.26M | $112,575 |
| Depreciation & amortization | $6,533 | $6,533 | $6,533 | $6,533 | $0 | $0 | $0 | $0 |
| Stock-based compensation | $405 | $1,870 | $8,743 | $24,339 | $45,858 | $90,638 | $16,251 | $30,149 |
Free plan shows the latest 8 periods; Pro shows all 36 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.